Corporate Governance - Peter H. Puccetti was elected as Chair with 580,289 votes, representing 88.92% approval[2] - Deloitte LLP was appointed as the Company's auditor with 1,043,647 votes in favor, accounting for 93.55%[13] - The Amended and Restated Shareholder Rights Plan was approved with 521,610 votes for, which is 79.93%[13] - Ronald W. Miller received the lowest approval at 68.75%, with 448,646 votes for and 203,929 votes against[2] - The voting results were filed on SEDAR+ and EDGAR for public access[4] Business Operations - The Company has a diversified portfolio including macimorelin, the first FDA and EMA approved oral test for adult growth hormone deficiency[5] - The Company is listed on both NASDAQ and TSX under the ticker symbol "CSCI"[6] - The Company has relied on an exemption from certain Canadian requirements regarding its long-term incentive plan[3] Risk Management - Forward-looking statements indicate potential risks related to product development and market performance[9] - The Company emphasizes the importance of securing strategic partners for late-stage development and marketing[9]
Cosciens Biopharma Inc(CSCI) - 2025 Q2 - Quarterly Report